169 related articles for article (PubMed ID: 38437992)
1. T cell infiltration mediates neurodegeneration and cognitive decline in Alzheimer's disease.
Zeng J; Liao Z; Yang H; Wang Q; Wu Z; Hua F; Zhou Z
Neurobiol Dis; 2024 Apr; 193():106461. PubMed ID: 38437992
[TBL] [Abstract][Full Text] [Related]
2. Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy.
Chen X; Firulyova M; Manis M; Herz J; Smirnov I; Aladyeva E; Wang C; Bao X; Finn MB; Hu H; Shchukina I; Kim MW; Yuede CM; Kipnis J; Artyomov MN; Ulrich JD; Holtzman DM
Nature; 2023 Mar; 615(7953):668-677. PubMed ID: 36890231
[TBL] [Abstract][Full Text] [Related]
3. Dysfunction of the blood-brain barrier in Alzheimer's disease: Evidence from human studies.
Kurz C; Walker L; Rauchmann BS; Perneczky R
Neuropathol Appl Neurobiol; 2022 Apr; 48(3):e12782. PubMed ID: 34823269
[TBL] [Abstract][Full Text] [Related]
4. Fibrillar Aβ triggers microglial proteome alterations and dysfunction in Alzheimer mouse models.
Sebastian Monasor L; Müller SA; Colombo AV; Tanrioever G; König J; Roth S; Liesz A; Berghofer A; Piechotta A; Prestel M; Saito T; Saido TC; Herms J; Willem M; Haass C; Lichtenthaler SF; Tahirovic S
Elife; 2020 Jun; 9():. PubMed ID: 32510331
[TBL] [Abstract][Full Text] [Related]
5. SLOH, a carbazole-based fluorophore, mitigates neuropathology and behavioral impairment in the triple-transgenic mouse model of Alzheimer's disease.
Wu X; Kosaraju J; Zhou W; Tam KY
Neuropharmacology; 2018 Mar; 131():351-363. PubMed ID: 29309769
[TBL] [Abstract][Full Text] [Related]
6. Clearance of Amyloid Beta and Tau in Alzheimer's Disease: from Mechanisms to Therapy.
Xin SH; Tan L; Cao X; Yu JT; Tan L
Neurotox Res; 2018 Oct; 34(3):733-748. PubMed ID: 29626319
[TBL] [Abstract][Full Text] [Related]
7. Role of TREM2 in Alzheimer's Disease and its Consequences on β- Amyloid, Tau and Neurofibrillary Tangles.
Singh AK; Mishra G; Maurya A; Awasthi R; Kumari K; Thakur A; Rai A; Rai GK; Sharma B; Kulkarni GT; Singh SK
Curr Alzheimer Res; 2019; 16(13):1216-1229. PubMed ID: 31481003
[TBL] [Abstract][Full Text] [Related]
8. APOE effects on regional tau in preclinical Alzheimer's disease.
Young CB; Johns E; Kennedy G; Belloy ME; Insel PS; Greicius MD; Sperling RA; Johnson KA; Poston KL; Mormino EC; ;
Mol Neurodegener; 2023 Jan; 18(1):1. PubMed ID: 36597122
[TBL] [Abstract][Full Text] [Related]
9. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
[TBL] [Abstract][Full Text] [Related]
10. Distinct relationships of amyloid-beta and tau deposition to cerebral glucose metabolic networks in Alzheimer's disease.
Sun X; Nie B; Zhao S; Ai L; Chen Q; Zhang T; Pan T; Wang L; Yin X; Zhang W; Shan B; Liu H; Liang S; Wang G
Neurosci Lett; 2020 Jan; 717():134699. PubMed ID: 31874218
[TBL] [Abstract][Full Text] [Related]
11. Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum.
Tosun D; Demir Z; Veitch DP; Weintraub D; Aisen P; Jack CR; Jagust WJ; Petersen RC; Saykin AJ; Shaw LM; Trojanowski JQ; Weiner MW;
Alzheimers Dement; 2022 Jul; 18(7):1370-1382. PubMed ID: 34647694
[TBL] [Abstract][Full Text] [Related]
12. P-tau and neurodegeneration mediate the effect of β-amyloid on cognition in non-demented elders.
Ma LZ; Hu H; Wang ZT; Ou YN; Dong Q; Tan L; Yu JT
Alzheimers Res Ther; 2021 Dec; 13(1):200. PubMed ID: 34911582
[TBL] [Abstract][Full Text] [Related]
13. Changes in the detergent-insoluble brain proteome linked to amyloid and tau in Alzheimer's Disease progression.
Hales CM; Dammer EB; Deng Q; Duong DM; Gearing M; Troncoso JC; Thambisetty M; Lah JJ; Shulman JM; Levey AI; Seyfried NT
Proteomics; 2016 Dec; 16(23):3042-3053. PubMed ID: 27718298
[TBL] [Abstract][Full Text] [Related]
14. Synaptic Loss, ER Stress and Neuro-Inflammation Emerge Late in the Lateral Temporal Cortex and Associate with Progressive Tau Pathology in Alzheimer's Disease.
Buchanan H; Mackay M; Palmer K; Tothová K; Katsur M; Platt B; Koss DJ
Mol Neurobiol; 2020 Aug; 57(8):3258-3272. PubMed ID: 32514860
[TBL] [Abstract][Full Text] [Related]
15. New Pathways Identify Novel Drug Targets for the Prevention and Treatment of Alzheimer's Disease.
Penke B; Szűcs M; Bogár F
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982456
[TBL] [Abstract][Full Text] [Related]
16. Dysfunctional microglia and tau pathology in Alzheimer's disease.
Ayyubova G
Rev Neurosci; 2023 Jun; 34(4):443-458. PubMed ID: 36302379
[TBL] [Abstract][Full Text] [Related]
17. The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer's disease.
Jazvinšćak Jembrek M; Slade N; Hof PR; Šimić G
Prog Neurobiol; 2018 Sep; 168():104-127. PubMed ID: 29733887
[TBL] [Abstract][Full Text] [Related]
18. Role of tau protein in Alzheimer's disease: The prime pathological player.
Muralidar S; Ambi SV; Sekaran S; Thirumalai D; Palaniappan B
Int J Biol Macromol; 2020 Nov; 163():1599-1617. PubMed ID: 32784025
[TBL] [Abstract][Full Text] [Related]
19. Molecular and Cellular Basis of Neurodegeneration in Alzheimer's Disease.
Jeong S
Mol Cells; 2017 Sep; 40(9):613-620. PubMed ID: 28927263
[TBL] [Abstract][Full Text] [Related]
20. Increased Aβ
Wang HY; Trocmé-Thibierge C; Stucky A; Shah SM; Kvasic J; Khan A; Morain P; Guignot I; Bouguen E; Deschet K; Pueyo M; Mocaer E; Ousset PJ; Vellas B; Kiyasova V
Alzheimers Res Ther; 2017 Jul; 9(1):54. PubMed ID: 28750690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
